Abstract
Novelty and Impact Statement: Our findings suggest that soluble folate receptor (sFR) could be used in both the initial diagnosis and surveillance of patients with ovarian cancer. Our cohort constitutes one of the largest comparison groups for sFR analyzed so far. We have defined the background level of sFR using healthy volunteers. This is also the first study to prospectively follow patients in the surveillance setting to concurrently identify differential changes in tumor markers CA‐125 and sFR.
Highlights
Ovarian cancer (OVCA) constitutes the deadliest gynecologic malignancy, with ~14 000 deaths anticipated in the United States in 2017.1 epithelial cancers display response rates of 80% to standard therapy, up to 70% of patients relapse within 2 years
In 2014, a study evaluating 2801 patients from the Ovarian Tumor Tissue Analysis (OTTA) consortium linked to data from the Cancer Genome Atlas (TCGA) established that folate receptor α (FR) was overexpressed in 76% of high‐grade serous ovarian carcinoma (HGSC).[4]
Our findings suggest that soluble form (sFR) can distinguish between healthy controls, benign patients and those with OVCA
Summary
Ovarian cancer (OVCA) constitutes the deadliest gynecologic malignancy, with ~14 000 deaths anticipated in the United States in 2017.1 epithelial cancers display response rates of 80% to standard therapy, up to 70% of patients relapse within 2 years. This poor prognosis is due to lack of early detection, as well as to innate and acquired resistance to chemotherapy.[2,3,4,5] while early‐stage OVCA is often cured by surgery, 60% diagnosed at Stage 3/4. There are limited data linking high sFR to shorter progression‐free survival (PFS).[9]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
